OpGen, Inc.

OpGen, Inc. is a biotechnology firm focused on advancing molecular diagnostic solutions for detecting drug-resistant infections, enhancing patient care through innovative diagnostic technology. Founded in 2002 and headquartered in Rockville, US, OpGen, Inc. specializes in molecular diagnostics aimed at optimizing treatment for drug-resistant infections.

The firm has executed a total of 18 deals, with its most recent funding round being a Private Placement/Follow on raising USD 11. 99 mn in May 2015. The company's operations have remained consistent since its founding, with no significant pivots mentioned. The current CEOs are Noel Doheny and Oliver Schacht.

OpGen develops advanced molecular diagnostic solutions focused on optimizing treatment for life-threatening, drug-resistant infections. Their flagship products include multiplexed syndromic molecular panels for swift and accurate pathogen detection, directly addressing antimicrobial resistance (AMR). These solutions are primarily utilized by hospitals and clinical laboratories across the US and Europe, integrating seamlessly into standard medical protocols to improve patient outcomes and healthcare quality. In the most recent fiscal year 2023, OpGen generated revenue of USD 3.

42 mn, while the EBITDA reported for the same year was USD -29. 43 mn, reflecting the company's ongoing investment in research and development. OpGen is focused on developing and launching new molecular diagnostic products to enhance its offerings against drug-resistant infections. The company aims to expand its market reach into additional geographic regions, particularly across Europe and emerging markets, by 2025.

Recent funding from its last round will support these initiatives, allowing OpGen to enhance product development and market penetration strategies.